What is it about?
Patients that require dialysis to replace their kidney function are at high risk of death related to heart problems. Aldosterone, a hormone, is linked to these types of heart related deaths. Eplerenone is a drug that blocks the action of aldosterone. In this study, we showed that eplerenone is well tolerated by patients that require dialysis but that it increases levels of blood potassium. This study also shows it is possible to proceed to a larger study that will determine whether eplerenone safely prevents heart related deaths.
Featured Image
Why is it important?
There are no proven therapies to reduce heart related deaths for patients that required dialysis. This study is an important first step to proving whether drugs that block aldosterone will prevent heart related deaths.
Read the Original
This page is a summary of: The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial, Clinical Journal of the American Society of Nephrology, July 2015, American Society of Nephrology,
DOI: 10.2215/cjn.12371214.
You can read the full text:
Contributors
The following have contributed to this page